The Anglo/Russian pharmaceutical company, Pro Bono Bio Group Plc, has reported promising pre-clinical data for a new group of haemophilia products that would act longer than existing blood factor proteins thereby enabling patients to self-administer treatments at home. The preclinical data still must be confirmed in human trials and approved by a regulator before any products could be marketed.
